A comparative study on the ventilatory and haemodynamic effects of xamoterol and atenolol in asthmatic patients
- PMID: 2878680
- PMCID: PMC1401187
- DOI: 10.1111/j.1365-2125.1986.tb02940.x
A comparative study on the ventilatory and haemodynamic effects of xamoterol and atenolol in asthmatic patients
Abstract
The effects of single oral doses of atenolol 50 mg and xamoterol 200 mg (a recently developed partial beta 1-adrenoceptor agonist) on lung function, heart rate and blood pressure were investigated in 11 patients with asthma. Xamoterol caused a significant increase in heart rate and systolic blood pressure, which changes are consistent with the partial beta 1-adrenoceptor agonist activity of this drug. Atenolol induced a significant decrease in FEV1 and the forced vital capacity (FVC); there was a non-significant change in FEV1 and FVC after xamoterol. There was no significant difference between the effects of atenolol and xamoterol of FEV1 and FVC. Bronchospasm induced by atenolol 50 mg and xamoterol 200 mg was completely reversed by inhalation of the beta 2-adrenoceptor agonist terbutaline to a cumulative dose of 4.0 mg.
Similar articles
-
Ventilatory effects of atenolol and bevantolol in asthma.Clin Pharmacol Ther. 1985 Oct;38(4):428-33. doi: 10.1038/clpt.1985.199. Clin Pharmacol Ther. 1985. PMID: 4042527 Clinical Trial.
-
Effects of xamoterol (ICI 118,587) in asthmatic patients.Br J Clin Pharmacol. 1984 Oct;18(4):597-601. doi: 10.1111/j.1365-2125.1984.tb02510.x. Br J Clin Pharmacol. 1984. PMID: 6148960 Free PMC article. Clinical Trial.
-
Effect of beta-adrenoceptor agents on the blood flow in carotid arteries in normal volunteers.Br J Clin Pharmacol. 1989;28 Suppl 1(Suppl 1):73S-74S. doi: 10.1111/j.1365-2125.1989.tb03578.x. Br J Clin Pharmacol. 1989. PMID: 2572260 Free PMC article. Clinical Trial.
-
[Noninvasive evaluation of partial beta adrenergic agonist properties of xamoterol in cardiac insufficiency].Arch Mal Coeur Vaiss. 1990 Feb;83(2):247-52. Arch Mal Coeur Vaiss. 1990. PMID: 1968739 Review. French.
-
Beta, partial agonists to treat heart failure: effects of xamoterol upon cardiac function and clinical status.Clin Cardiol. 1990 Mar;13(3):171-6. doi: 10.1002/clc.4960130305. Clin Cardiol. 1990. PMID: 1969783 Review.
Cited by
-
Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling.Trends Pharmacol Sci. 2011 Apr;32(4):227-34. doi: 10.1016/j.tips.2011.02.010. Epub 2011 Mar 21. Trends Pharmacol Sci. 2011. PMID: 21429598 Free PMC article. Review.
-
Beta-adrenoceptor partial agonists: a renaissance in cardiovascular therapy?Br J Clin Pharmacol. 1990 Aug;30(2):157-71. doi: 10.1111/j.1365-2125.1990.tb03760.x. Br J Clin Pharmacol. 1990. PMID: 1976342 Free PMC article. Review. No abstract available.
-
Is xamoterol safe in chronic airflow obstruction?Eur J Clin Pharmacol. 1992;42(2):147-50. doi: 10.1007/BF00278474. Eur J Clin Pharmacol. 1992. PMID: 1352245 Clinical Trial.
-
Xamoterol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.Drugs. 1988 Oct;36(4):455-74. doi: 10.2165/00003495-198836040-00004. Drugs. 1988. PMID: 2906865 Review.
-
Cardioselective beta-blocker use in patients with reversible airway disease.Cochrane Database Syst Rev. 2001;2002(2):CD002992. doi: 10.1002/14651858.CD002992. Cochrane Database Syst Rev. 2001. Update in: Cochrane Database Syst Rev. 2002;(1):CD002992. doi: 10.1002/14651858.CD002992. PMID: 11406056 Free PMC article. Updated.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical